Literature DB >> 25895640

Differences in the profile of protection afforded by TRO40303 and mild hypothermia in models of cardiac ischemia/reperfusion injury.

Magnus J Hansson1, Osian Llwyd2, Didier Morin3, Damien de Paulis4, Thomas Arnoux5, Caroline Gouarné6, Sasha Koul7, Henrik Engblom8, Thierry Bordet9, Renaud Tissier10, Haakan Arheden11, David Erlinge12, Andrew P Halestrap13, Alain Berdeaux14, Rebecca M Pruss15, Sophie Schaller16.   

Abstract

The mode of protection against cardiac reperfusion injury by mild hypothermia and TRO40303 was investigated in various experimental models and compared to MitoQ in vitro. In isolated cardiomyocytes subjected to hypoxia/reoxygenation, TRO40303, MitoQ and mild hypothermia delayed mPTP opening, inhibited generation of mitochondrial superoxide anions at reoxygenation and improved cell survival. Mild hypothermia, but not MitoQ and TRO40303, provided protection in a metabolic starvation model in H9c2 cells and preserved respiratory function in isolated rat heart mitochondria submitted to anoxia/reoxygenation. In the Langendorff-perfused rat heart, only mild hypothermia provided protection of hemodynamic function and reduced infarct size following ischemia/reperfusion. In biopsies from the left ventricle of pigs subjected to in vivo occlusion/reperfusion, TRO40303 specifically preserved respiratory functions in the peri-infarct zone whereas mild hypothermia preserved both the ischemic core area and the peri-infarct zones. Additionally in this pig model, only hypothermia reduced infarct size. We conclude that mild hypothermia provided protection in all models by reducing the detrimental effects of ischemia, and when initiated before occlusion, reduced subsequent reperfusion damage leading to a smaller infarct. By contrast, although TRO40303 provided similar protection to MitoQ in vitro and offered specific protection against some aspects of reperfusion injury in vivo, this was insufficient to reduce infarct size.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MitoQ (PubChem CID: 11388331); Mode of protection; Myocardial infarction; Reperfusion injury; TRO40303 (PubChem CID: 11524274)

Mesh:

Substances:

Year:  2015        PMID: 25895640     DOI: 10.1016/j.ejphar.2015.04.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  The mitochondria-targeted antioxidant MitoQ ameliorates myocardial ischemia-reperfusion injury by enhancing PINK1/Parkin-mediated mitophagy in type 2 diabetic rats.

Authors:  Yelong Ji; Yan Leng; Shaoqing Lei; Zhen Qiu; Hao Ming; Yi Zhang; Aining Zhang; Yang Wu; Zhongyaun Xia
Journal:  Cell Stress Chaperones       Date:  2022-04-15       Impact factor: 3.827

2.  Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?

Authors:  Maaike Te Lintel Hekkert; Gary Newton; Dirk J Duncker; Michael D Schneider; Kathryn Chapman; Rehan Aqil; Robert Downham; Robert Yan; Daphne Merkus; Gavin Whitlock; Charlotte A L Lane; Darren Cawkill; Trevor Perrior
Journal:  Basic Res Cardiol       Date:  2021-05-20       Impact factor: 17.165

3.  Real-Time Fluorescence Measurements of ROS and [Ca2+] in Ischemic / Reperfused Rat Hearts: Detectable Increases Occur only after Mitochondrial Pore Opening and Are Attenuated by Ischemic Preconditioning.

Authors:  Tatyana Andrienko; Philippe Pasdois; Andreas Rossbach; Andrew P Halestrap
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 4.  The role of succinate and ROS in reperfusion injury - A critical appraisal.

Authors:  Tatyana N Andrienko; Philippe Pasdois; Gonçalo C Pereira; Matthew J Ovens; Andrew P Halestrap
Journal:  J Mol Cell Cardiol       Date:  2017-07-05       Impact factor: 5.000

5.  Neuroprotective effects of ammonium tetrathiomolybdate, a slow-release sulfide donor, in a rodent model of regional stroke.

Authors:  Bruna Pescador Mendonça; Juliano Dos Santos Cardoso; Monique Michels; Ana Carolina Vieira; Diogo Wendhausen; Andressa Manfredini; Mervyn Singer; Felipe Dal-Pizzol; Alex Dyson
Journal:  Intensive Care Med Exp       Date:  2020-04-09

6.  A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data.

Authors:  Henrik Engblom; Jane Tufvesson; Robert Jablonowski; Marcus Carlsson; Anthony H Aletras; Pavel Hoffmann; Alexis Jacquier; Frank Kober; Bernhard Metzler; David Erlinge; Dan Atar; Håkan Arheden; Einar Heiberg
Journal:  J Cardiovasc Magn Reson       Date:  2016-05-04       Impact factor: 5.364

7.  Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.

Authors:  Derek J Hausenloy; Hans Erik Botker; Thomas Engstrom; David Erlinge; Gerd Heusch; Borja Ibanez; Robert A Kloner; Michel Ovize; Derek M Yellon; David Garcia-Dorado
Journal:  Eur Heart J       Date:  2017-04-01       Impact factor: 29.983

Review 8.  Mitochondria in acute myocardial infarction and cardioprotection.

Authors:  Chrishan J A Ramachandra; Sauri Hernandez-Resendiz; Gustavo E Crespo-Avilan; Ying-Hsi Lin; Derek J Hausenloy
Journal:  EBioMedicine       Date:  2020-07-10       Impact factor: 8.143

9.  Sinapine, but not sinapic acid, counteracts mitochondrial oxidative stress in cardiomyocytes.

Authors:  Doria Boulghobra; Pierre-Edouard Grillet; Mickaël Laguerre; Mathieu Tenon; Jérémy Fauconnier; Pascale Fança-Berthon; Cyril Reboul; Olivier Cazorla
Journal:  Redox Biol       Date:  2020-05-19       Impact factor: 11.799

Review 10.  Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST-segment elevation myocardial infarction.

Authors:  Hans Erik Bøtker; Hector Alejandro Cabrera-Fuentes; Marisol Ruiz-Meana; Gerd Heusch; Michel Ovize
Journal:  J Cell Mol Med       Date:  2020-01-22       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.